Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.11 (57.08% upside)

Current Analysts' Coverage Summary for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
5/23/2014HC WainwrightReiterated RatingBuy$19.00ViewTweet This Rating  Share This Rating on StockTwits
5/12/2014MLV & Co Lower Price TargetBuy$27.00 -> $21.00ViewTweet This Rating  Share This Rating on StockTwits
5/9/2014MizuhoLower Price Target$34.00 -> $32.00ViewTweet This Rating  Share This Rating on StockTwits
5/9/2014JMP SecuritiesLower Price Target$25.00 -> $19.00ViewTweet This Rating  Share This Rating on StockTwits
4/4/2014Ladenburg ThalmannBoost Price TargetBuy$24.00 -> $30.00ViewTweet This Rating  Share This Rating on StockTwits
4/1/2014OppenheimerBoost Price TargetOutperform$20.00 -> $22.00ViewTweet This Rating  Share This Rating on StockTwits
3/14/2014Stifel NicolausBoost Price TargetBuy$17.00 -> $19.00ViewTweet This Rating  Share This Rating on StockTwits
1/27/2014Maxim GroupBoost Price TargetBuy$16.00 -> $25.00ViewTweet This Rating  Share This Rating on StockTwits
1/21/2014Roth CapitalBoost Price Target$30.00ViewTweet This Rating  Share This Rating on StockTwits
11/7/2013JPMorgan Chase & Co.Reiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
11/5/2013Brean CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
11/27/2012Dawson JamesInitiated CoverageOutperform$4.00ViewTweet This Rating  Share This Rating on StockTwits
11/13/2012Burrill Institutional ResearchInitiated CoverageOutperform$6.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2012 forward)